Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HCW Biologics (HCWB) EBT (2020 - 2025)

HCW Biologics (HCWB) has disclosed EBT for 6 consecutive years, with -$3.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT rose 11.96% year-over-year to -$3.4 million, compared with a TTM value of -$12.7 million through Sep 2025, up 66.0%, and an annual FY2024 reading of -$30.1 million, down 15.81% over the prior year.
  • EBT was -$3.4 million for Q3 2025 at HCW Biologics, up from -$3.7 million in the prior quarter.
  • Across five years, EBT topped out at -$1.9 million in Q1 2022 and bottomed at -$15.3 million in Q2 2024.
  • Average EBT over 5 years is -$4.9 million, with a median of -$3.9 million recorded in 2024.
  • The sharpest move saw EBT plummeted 232.08% in 2024, then surged 76.0% in 2025.
  • Year by year, EBT stood at -$3.1 million in 2021, then plummeted by 85.11% to -$5.8 million in 2022, then plummeted by 86.87% to -$10.8 million in 2023, then surged by 68.4% to -$3.4 million in 2024, then decreased by 1.11% to -$3.4 million in 2025.
  • Business Quant data shows EBT for HCWB at -$3.4 million in Q3 2025, -$3.7 million in Q2 2025, and -$2.2 million in Q1 2025.